Year: 2022
Type: review
Abstract: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by a complex and dysfunctional immune response. Currently, IBD is incurable, and patients with IBD often need to take drugs for life. However, as the traditional systemic treatment strategies for IBD do not target the site of inflammation, only limited efficacy can be obtained from them. Moreover, the possibility of serious side effects stemming from the systemic administration or redistribution of drugs in the body is high when conventional drug formulations are used. Therefore, a targeted drug-delivery system for IBD should be considered. Based on the pathological features related to IBD, the new targeted drug-delivery strategy can directly transfer the drug to the inflammatory site, thus enhancing the accumulation of the drugs and reducing side effects. This article reviews the pathological features of IBD and the application of the IBD-targeted delivery system based on different pathological features, and discusses the challenges and new prospects in this field.
Source: Biomedicine & Pharmacotherapy
Authors: Shanshan Li, Fuzhong Zhang, Qixiong Zhang
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,740
Funders: Ministry of Science and Technology of the People's Republic of China, National University's Basic Research Foundation of China, Southwest Minzu University, Sichuan Province Science and Technology Support Program, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities
OpenAlex ID: W4281560681